Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0428 USD | +4.99% | -.--% | -4.89% |
18/04 | RepliCel Life Sciences Inc. Announces Secured Loan Agreement | CI |
2023 | RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Business Summary
Number of employees: 1
Sales per Business
CAD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Cell Replication Technology
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -.--% |
Sales per region
CAD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Canada
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -.--% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Andrew Schutte
CEO | Chief Executive Officer | 35 | 14/18/14 |
Rolf Hoffmann
FOU | Founder | 63 | - |
Kevin McElwee
FOU | Founder | 54 | - |
David Kwok
DFI | Director of Finance/CFO | - | 16/23/16 |
David Hall
CHM | Chairman | 71 | 22/10/22 |
Ben Austring
COO | Chief Operating Officer | 41 | 28/22/28 |
Robert Buckler
BRD | Director/Board Member | 58 | 01/14/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Hall
CHM | Chairman | 71 | 22/10/22 |
Peter Lewis
BRD | Director/Board Member | 69 | 27/11/27 |
Rolf Hoffmann
FOU | Founder | 63 | - |
Robert Buckler
BRD | Director/Board Member | 58 | 01/14/01 |
Gary Boddington
BRD | Director/Board Member | 56 | 01/21/01 |
Andrew Schutte
CEO | Chief Executive Officer | 35 | 14/18/14 |
Peter Lowry
BRD | Director/Board Member | 61 | 14/18/14 |
Jamie Mackay
BRD | Director/Board Member | - | 09/23/09 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 61,426,772 | 24,249,871 ( 39.48 %) | 0 | 39.48 % |
Company contact information
RepliCel Life Sciences, Inc.
570 Granville Street Suite 900
V6C 3P1, Vancouver
+604 248 8730
http://www.replicel.comSector
1st Jan change | Capi. | |
---|---|---|
-4.89% | 2.78M | |
+2.99% | 108B | |
+10.35% | 105B | |
+1.57% | 23.46B | |
-12.61% | 21.72B | |
-7.05% | 18.64B | |
-37.64% | 17.45B | |
-7.42% | 17.19B | |
+6.18% | 13.99B | |
+38.02% | 12.53B |
- Stock Market
- Equities
- REPCF Stock
- Company RepliCel Life Sciences Inc.